A novel human-based receptor antagonist of sustained action reveals body weight control by endogenous GLP-1
Getting access is becoming easier
Eli Lilly partnered with Fauna Bio to explore novel targets beyond GLP-1s, looking for ways to help humans maintain healthy metabolism during weight loss
The authors have given talks and attended conferences sponsored by various pharmaceutical companies, including Bristol-Myers Squibb, Pfizer, Lilly, Abbott, Amgen, Astrazeneca, Novartis, Vianex, Teva, and MSD
These foods may provide rapid glucose spikes without the sustained hormonal response that whole foods elicit
Data Validation and Update Cycle: Findings are validated by comparing primary interviews with public data, company activity, regulatory changes, trade patterns, and industry developments